ArticleFrontiers in immunology2025
Therapeutic drug monitoring plays an important role in patients with noninfectious uveitis receiving adalimumab.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of serum adalimumab levels and immunogenicity with clinical response in non-infectious uveitis: a real-world cohort study.Frontiers in immunology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the association between serum adalimumab (ADA) concentrations, antibodies against adalimumab (AAAs), tumor necrosis factor α (TNFα) levels, and clinical response in patients with noninfectious uveitis (NIU), as well as changes in TNFα after administration of ADA, to explore the role of therapeutic drug monitoring in these patients. Methods: This retrospective study included NIU patients treated with ADA at Peking Union Medical College Hospital between June 2024 and April 2025, who underwent testing for serum ADA and AAA levels. Most patients also had serum TNFα measured concurrently. Clinical data collected included concomitant medications, ADA dosing frequency, and ocular inflammation status, etc. High-performance size-exclusion chromatography was used to characterize forms of TNFα in serum samples of patients. THP-1 cells were stimulated with free TNFα or TNFα-ADA complexes to compare their pro-inflammatory activity. Results: Among 164 test results from 147 patients included (aged 5~56 years), median ADA level was significantly lower in AAA-positive patients than in AAA-negative patients (1.9 vs. 6.4 μg/mL; P<0.001), and lower in those with active inflammation than in those with quiescent inflammation (2.2 vs. 6.0 μg/mL; P<0.001). An ADA level below 4.1 μg/mL was associated with poor clinical response. Concomitant antimetabolite use was linked to a lower proportion of detectable AAAs compared with ADA monotherapy (34.3% vs. 54.5%; P = 0.036). Median ADA level was significantly higher when testing occurred ≤14 days after the last dose of ADA (P<0.001), though many patients maintained therapeutic levels even with extended dosing intervals. TNFα levels increased in most patients after ADA therapy, predominantly in the form of TNFα-ADA complexes, which exhibited significantly weaker pro-inflammatory effects than free TNFα. Conclusion: The presence of AAAs was associated with reduced ADA levels and an increased risk of treatment failure. Despite the limitations of a retrospective design, these findings suggest that therapeutic drug monitoring may help identify causes of treatment failure and optimize regimens in stable patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.